参考文献/References:
[1] Chmiela M,Gajewski A,Rudnicka K,et al.Helicobacter pylori vs coronary heart disease-searching for connections[J].World J Cardiol,2015,7(4):187-203.
[2] Stone AF,Mendall MA.Helicobacter pylori is an aetiological factor for ischaemic heart disease:The case in favour[J].Dig Liver Dis,2000,32(1):62-64.
[3] 赵燕颖,程海涛,王志军,等.冠状动脉粥样硬化性心脏病与幽门螺杆菌感染的相关性[J].世界华人消化杂志,2016,24(10):1613-1617.
[4] Jukic A,Bozic D,Kardum D,et al.Helicobacter pylori infection and severity of coronary atherosclerosis in patients with chronic coronary artery disease[J].Ther Clin Risk Manag,2017,13:933-938.
[5] Liu J,Wang F,Shi S,et al.Helicobacter pyloriInfection increase the risk of myocardial infarction:A meta-analysis of 26 studies involving more than 20,000 participants[J].Helicobacter,2014,20(3):176-183.
[6] Chauhan N,Tay ACY,Marshall BJ,et al.Helicobacter pylori VacA,a distinct toxin exerts diverse functionalities in numerous cells:An overview[J].Helicobacter,2018,24(1):e12544.
[7] 刘士程,侯云修.幽门螺杆菌CagA阳性菌株感染与动脉粥样硬化的研究进展[J].现代医学与健康研究,2020,11(4):116-118.
[8] 张 丽,张保朝,王 璐,等.冠状动脉粥样硬化性心脏病患者细胞毒素相关蛋白基因A幽门螺杆菌感染状况研究[J].中华医院感染学杂志,2017,27(13):2928-2931.
[9] Jamkhande PG,Gattani SG,Farhat S,et al.A helicobacter pylori and cardiovascular complications:A mechanism based review on role of helicobacter pylori in cardiovascular diseases[J].Integr Med Res,2016,5(4):244-249.
[10] Ninomiya R,Kubo S,Baba T,et al.Inhibition of low-density lipoprotein uptake by helicobacter pylori virulence factor CagA[J].Biochem Biophys Res Commun,2021,9(1):192-198.
[11] Yang S,Xia YP,Luo XY,et al.Exosomal CagA derived from helicobacter pylori-infected gastric epithelial cells induces macrophage foam cell formation and promotes atherosclerosis[J].JMCC,2019,135:40-51.
[12] Konieczna I,Zarnowiec P,Kwinkowski M,et al.Bacterial urease and its role in long-lasting human diseases[J].Curr Proeitn & Pept Sci,2012,13(8):789-806.
[13] 赵慧琳,季晓飞,张艳丽,等.分子伴侣幽门螺杆菌Hsp60与UreB的相互作用分析[J].中国病原生物学,2016,11(11):977-981.
[14] Corrado E,Novo S.Role of inflammation and infection in vascular disease[J].Acta Chir Belg,2016,105(6):67-79.
[15] 井立省,王德昭,邹爱春,等.幽门螺杆菌和血浆基质金属蛋白酶-9与冠心病的相关性[J].中国老年学杂志,2017,37(22):55-60.
[16] 张国英.血清HIF-1α和VEGF与冠心病严重程度的相关性[J].中西医结合心脑血管病杂志,2021,19(5):879-880.
[17] Zhang Z,Yao L,Yang J,et al.PI3K/Akt and HIF1 signaling pathway in hypoxia-ischemia[J].Mol Med Rep,2018,18(4):3547-3554.
[18] 张文才,杨 帆,宫俊龙,等.冠心病患者血管内皮细胞生长因子水平与幽门螺杆菌感染情况的关系[J].中国循证心血管医学杂志,2019,11(1):29-31.
[19] Chi J,Xia X,Zhang L,et al.Helicobacter pylori induces GATA3-dependent chitinase 3 like 1(CHI3L1)upregulation and contributes to vascular endothelial injuries[J].Med Sci Monit,2019,25(12):4837-4848.
[20] Xia X,Zhang L,Chi J,et al.Helicobacter pylori infection impairs endothelial function through an exosome-mediated mechanism[J].J Am Heart Assoc,2020,9(6):e014120.
[21] Agnieszka M,Maciej C,Marlena B,et al.Putative consequences of exposure to helicobacter pylori infection in patients with coronary heart disease in terms of humoral immune response and inflammation[J].Archives of Medical Science,2016,12(1):45-54.
[22] Thiruvelselvan P,Venkatachala SK,Manjunatha R,et al.Inverse association of ApoB and HSP60 antibodies with coronary artery disease in Indian population[J].Heart Asia,2018,10(2):11-18.
[23] 邵光威.细胞毒素相关基因蛋白A抗体阳性HP感染对急性心肌梗死患者发病影响的研究[J].青岛医药卫生,2019,51(4):241-245.
[24] 黄 勇,李蔚华,尹 虹,等.冠心病患者幽门螺杆菌感染与斑块特征、脂代谢、炎症反应的相关性[J].中国动脉硬化杂志,2019,27(8):713-717.
[25] Krupa A,Gonciarz W,Rusek-Wala P,et al.Helicobacter pylori infection acts synergistically with a high-fat diet in the development of a proinflammatory and potentially proatherogenic endothelial cell environment in an experimental model[J].Int J Mol Sci,2021,22(7):2-27.
[26] 席新龙,王 君,赵 棉,等.同型半胱氨酸与冠心病、尿酸及血脂的相关性研究[J].陕西医学杂志,2018,47(11):1471-1473.
[27] Novák P,Jackson AO,Zhao GJ,et al.Bilirubin in metabolic syndrome and associated inflammatory diseases:New perspectives[J].Life Sciences,2020,257:118032.
[28] Wang JW,Tseng KL,Hsu CN,et al.Association between helicobacter pylori eradication and the risk of coronary heart diseases[J].PLoS One,2018,13(1):e0190219.
[29] Ashida K,Honda Y,Sanada K,et al.The safety and effectiveness of vonoprazan-based helicobacter pylori eradication therapy; a prospective post-marketing surveillance[J].Expert Opinion on Drug Safety,2019,18(12):1255-1261.
[30] Cárdenas PA,Garcés D,Prado-Vivar B,et al.Effect of saccharomyces boulardii CNCM I-745 as complementary treatment of helicobacter pylori infection on gut microbiome[J].Eur J Clin Microbiol Infect Dis,2020,39:1365-1372.
[31] 蔡 博,田 蕾.地衣芽孢杆菌联合铋剂四联疗法根除幽门螺杆菌感染临床研究[J].陕西医学杂志,2020,49(8):1032-1034,1048.
[32] Yang J,Song H,Cao K,et al.Comprehensive analysis of Helicobacter pylori infection-associated diseases based on miRNA-mRNA interaction network[J].Briefings in Bioinformatics,2019,20(4):1492-1501.
[33] 夏铭蔚,邵正斌,梁国庆,等.冠心病患者血浆中miR-126水平与其冠状动脉侧支循环系统形成及预后的关系[J].广东医学,2018,39(14):2179-2182.
[34] 艾世宜,李佳娜,李 星.miRNA-126和miRNA-92a在冠心病患者血清中的表达水平及临床意义[J].陕西医学杂志,2021,50(4):443-446.
[35] Ridker PM.From CANTOS to CIRT to COLCOT to clinic:Will all atheroslcerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? [J].Circulation,2020,141(10):787-789.
相似文献/References:
[1]张彦亭,杨振威,原姗姗,等.不同分型幽门螺杆菌感染消化性溃疡患者血清胃蛋白酶原、共刺激分子CD40、α防御素表达及检测意义[J].陕西医学杂志,2020,49(10):1310.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.029]
[2]吴 晋.替普瑞酮治疗老年HP阳性慢性萎缩性胃炎临床效果分析[J].陕西医学杂志,2021,50(6):735.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.024]
[3]吴水清,黄建成,李达周,等.OLGA及OLGIM分期系统对1790例慢性萎缩性胃炎患者胃癌风险的评估价值[J].陕西医学杂志,2021,50(6):756.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.029]
WU Shuiqing,HUANG Jiancheng,LI Dazhou,et al.Value of OLGA and OLGIM staging system in evaluating the risk of gastric cancer in 1790 patients with chronic atrophic gastritis[J].,2021,50(9):756.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.029]
[4]刘应红,罗 波,张宗霞,等.铝碳酸镁联合三联疗法治疗幽门螺杆菌阳性消化性溃疡疗效及对患者幽门螺杆菌根除率及Treg/Th17平衡的影响[J].陕西医学杂志,2023,52(5):591.[doi:DOI:10.3969/j.issn.1000-7377.2023.05.022]
LIU Yinghong,LUO Bo,ZHANG Zongxia,et al.Effects of hydrotalcite combined with triple therapy on helicobacter pylori eradication rate and Treg/Th17 balance in HP-positive peptic ulcer[J].,2023,52(9):591.[doi:DOI:10.3969/j.issn.1000-7377.2023.05.022]
[5]董佳鑫,王海艳,NOUTCHIE VINYE Nana(喀麦隆),等.幽门螺杆菌感染致表皮生长因子及其受体表达上调与胃癌发生及发展机制关系研究进展[J].陕西医学杂志,2024,(6):853.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.028]
DONG Jiaxin,WANG Haiyan,NOUTCHIE VINYE Nana,et al.Research progress on relationship between up-regulation of EGF/EGFR expression caused by Helicobacter pylori and mechanism of gastric cancer development[J].,2024,(9):853.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.028]
[6]张 琳,郭珊岚,康乐平.胃癌组织MutS同源物6、减数分裂后分离增强基因2表达与幽门螺杆菌感染及预后相关性研究[J].陕西医学杂志,2025,54(3):408.[doi:DOI:10.3969/j.issn.1000-7377.2025.03.024]
ZHANG Lin,GUO Shanlan,KANG Leping.Correlation of MSH6 and PMS2 expression with Helicobacter pylori infection and prognosis of gastric cancer[J].,2025,54(9):408.[doi:DOI:10.3969/j.issn.1000-7377.2025.03.024]